US FDA declines to approve injection form of J&J’s lung cancer drug
The U.S. Food and Drug Administration has declined to approve an injectable version of Johnson & Johnson’s drug Rybrevant for a type of lung cancer, the drugmaker said on Monday.
Related Articles
FDA Approves Nemolizumab for Individuals with Atopic Dermatitis
This approval announcement by Galderma follows the previous FDA approval of nemolizumab for prurigo nodularis.
Can Remixing Memory Curb AI’s Energy Problem?
TSMC’s former R&D; chief wants designers to combine different memory technologies
Vertebral Body Tethering Is a Promising Alternative to Spinal Fusion Surgery
Only a handful of orthopaedic surgeons in the U.S. are using the vertebral body tethering technique to treat idiopathic scoliosis.
The ‘Forbidden Toys’ Series Proves that There is a Place for AI in the Arts – PRINT Magazine
We chat with the artist behind the Forbidden Toys series which uses dark humor and AI to imagine sick and twisted toys and games for…
AI startups can apply for our Google for Startups Cloud AI Accelerator now
Learn more about Google for Startups Accelerator: AI First program for North American startups.
Three major health care policy issues to watch in 2025
Previewing health care policy under Trump: Medicaid cuts, Affordable Care Act premium subsidies, and Medicare reforms.
Bosses struggle to police workers’ use of AI
Staff are adopting large language models faster than companies can issue guidelines on how to do so
Merck discontinues development of 2 experimental cancer drugs after trial failures
Merck said on Monday it has discontinued the development of two experimental cancer drugs after their failure in several trials.
Rare myxoid pleomorphic liposarcoma: a case report and literature review
We report a case of a middle-aged woman with a rapidly growing abdominal mass that was diagnosed as myxoid pleomorphic liposarcoma, a recently recognised, rare…
The most popular AI tools of 2024 (and what that even means)
Want to know which AI tools businesses and creators are flocking to? Here’s 2024’s AI leaderboard and how ChatGPT, Canva, Gemini, Copilot, and more stack…